West Pharmaceutical Services (WST)
(Delayed Data from NYSE)
$256.64 USD
-1.71 (-0.66%)
Updated Sep 17, 2025 04:00 PM ET
After-Market: $256.67 +0.03 (0.01%) 7:58 PM ET
1-Strong Buy of 5 1
D Value D Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
WST 256.64 -1.71(-0.66%)
Will WST be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for WST based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for WST
BWAY Shares Gain on FDA Nod for Accelerated Deep TMS Depression Care
CAH Strengthens Distribution With New Consumer Health Logistics Hub
WST: What are Zacks experts saying now?
Zacks Private Portfolio Services
GEHC Expands Women's Health Portfolio With AI-Enabled Voluson
ISRG Stock Dips Despite Introducing Real-Time Insights on da Vinci 5
GEHC Eyes icometrix Buyout to Strengthen Neurology Imaging Portfolio
Other News for WST
WST rises 0.32% on September 16, leaving the technical picture intact
Optimistic Long-Term Growth Outlook for Wingstop Amid Strategic Initiatives and Expansion Plans
Is WST consolidating before a move? NR7 shows up after gaining 1.59%
Rothschild & Co Initiates Coverage on WST with a 'Buy' Rating | WST Stock News
West Pharmaceutical Services (WST) Has a New Rating from Redburn Atlantic